Pentraxins in the activation and regulation of innate immunity

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 202-217

  Daigo, Kenji ^a   Inforzato, Antonio ^a,b   Barajon, Isabella ^c   Garlanda, Cecilia ^a   Bottazzi, Barbara ^a   Meri, Seppo ^d   Mantovani, Alberto ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS UNIVERSITY   (Italy)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

cancer related inflammation; complement activation; inflammation; opsonization; pentraxins; PTX3

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD11B ANTIGEN; CD18 ANTIGEN; CD32 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; DECTIN 1; FC RECEPTOR; FICOLIN; MANNOSE BINDING LECTIN; OPSONIN; PATTERN RECOGNITION RECEPTOR; PENTRAXIN; PENTRAXIN 3; PROPERDIN; C REACTIVE PROTEIN; SERUM AMYLOID P; TUMOR MARKER;

CARBOXY TERMINAL SEQUENCE; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIAGNOSTIC VALUE; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TISSUE INJURY; TUMOR GROWTH; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM;

ANIMALS; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; MICE; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION; SERUM AMYLOID P-COMPONENT;

EID: 84992449527     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12476     Document Type: Review

References (174)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.
2. Garlanda C, Riva F, Bonavita E, Gentile S, Mantovani A. Decoys and regulatory “receptors” of the IL-1/Toll-like receptor superfamily. Frontiers Immunol. 2013;4:180.
3. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157–183.
4. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366.
5. Doni A, Musso T, Morone D, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. 2015;212:905–925.
6. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204:793–804.
7. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264:295–314.
8. Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
9. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40.
10. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2005;102:8309–8314.
11. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217–1221.
12. Bonavita E, Gentile S, Rubino M, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015;160:700–714.
13. Bottazzi B, Santini L, Savino S, et al. Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. PLoS ONE. 2015;10:e0120807.
14. Jaillon S, Moalli F, Ragnarsdottir B, et al. The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity. 2014;40:621–632.
15. Garlanda C, Jaillon S, Doni A, Bottazzi B, Mantovani A. PTX3, a humoral pattern recognition molecule at the interface between microbe and matrix recognition. Curr Opin Immunol. 2016;38:39–44.
16. Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64:1416–1427.
17. Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370:421–432.
18. Soares AC, Souza DG, Pinho V, et al. Dual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic mice. Microbes Infect. 2006;8:1321–1329.
19. Souza DG, Amaral FA, Fagundes CT, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol. 2009;174:1309–1318.
20. Inforzato A, Doni A, Barajon I, et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol. 2013;25:79–85.
21. Foo SS, Chen W, Taylor A, et al. Role of pentraxin 3 in shaping arthritogenic alphaviral disease: from enhanced viral replication to immunomodulation. PLoS Pathog. 2015;11:e1004649.
22. Ronca R, Giacomini A, Di Salle E, et al. Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell. 2015;28:225–239.
23. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med. 2007;11:723–738.
24. Carrizzo A, Lenzi P, Procaccini C, et al. Pentraxin 3 induces vascular endothelial dysfunction through a P-selectin/matrix metalloproteinase-1 pathway. Circulation. 2015;131:1495–1505.
25. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817–32823.
26. Daigo K, Nakakido M, Ohashi R, et al. Protective effect of the long pentraxin PTX3 against histone-mediated endothelial cell cytotoxicity in sepsis. Sci Signaling. 2014;7:ra88.
27. Goodman AR, Cardozo T, Abagyan R, Altmeyer A, Wisniewski HG, Vilcek J. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev. 1996;7:191–202.
28. Inforzato A, Peri G, Doni A, et al. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry (Mosc). 2006;45:11540–11551.
29. Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–1872.
30. Inforzato A, Baldock C, Jowitt TA, et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem. 2010;285:17681–17692.
31. Inforzato A, Rivieccio V, Morreale AP, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem. 2008;283:10147–10161.
32. Bozza S, Campo S, Arseni B, et al. PTX3 binds MD-2 and promotes TRIF-dependent immune protection in aspergillosis. J Immunol. 2014;193:2340–2348.
33. Leali D, Inforzato A, Ronca R, et al. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol. 2012;32:696–703.
34. Moalli F, Doni A, Deban L, et al. Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood. 2010;116:5170–5180.
35. Scarchilli L, Camaioni A, Bottazzi B, et al. PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem. 2007;282:30161–30170.
36. Deban L, Castro Russo R, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11:328–334.
37. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol. 2003;24:148–154.
38. Deban L, Jarva H, Lehtinen MJ, et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol. 2008;181:8433–8440.
39. Reading PC, Bozza S, Gilbertson B, et al. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol. 2008;180:3391–3398.
40. Inforzato A, Reading PC, Barbati E, Bottazzi B, Garlanda C, Mantovani A. The “sweet” side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation. Front Immunol. 2013;3:407.
41. Shrive AK, Metcalfe AM, Cartwright JR, Greenhough TJ. C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. J Mol Biol. 1999;290:997–1008.
42. Ievoli E, Lindstedt R, Inforzato A, et al. Implication of the oligomeric state of the N-terminal PTX3 domain in cumulus matrix assembly. Matrix Biol. 2011;30:330–337.
43. Baranova NS, Inforzato A, Briggs DC, et al. Incorporation of pentraxin 3 into hyaluronan matrices is tightly regulated and promotes matrix cross-linking. J Biol Chem. 2014;289:30481–30498.
44. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186.
45. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456:989–992.
46. Diniz SN, Nomizo R, Cisalpino PS, et al. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol. 2004;75:649–656.
47. Moalli F, Paroni M, Veliz Rodriguez T, et al. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol. 2011;186:5425–5434.
48. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812.
49. Thiel S, Gadjeva M. Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv Exp Med Biol. 2009;653:58–73.
50. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169–177.
51. Oliveira EB, Gotschlich C, Liu TY. Primary structure of human C-reactive protein. J Biol Chem. 1979;254:489–502.
52. Amarilyo G, Verbovetski I, Atallah M, et al. iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kappaB-dependent blockade. Eur J Immunol. 2010;40:699–709.
53. Skattum L, van Deuren M, van der Poll T, Truedsson L. Complement deficiency states and associated infections. Mol Immunol. 2011;48:1643–1655.
54. Jiang HX, Siegel JN, Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol. 1991;146:2324–2330.
55. Bristow CL, Boackle RJ. Evidence for the binding of human serum amyloid P component to Clq and Fab gamma. Mol Immunol. 1986;23:1045–1052.
56. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003;33:465–473.
57. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today. 1994;15:67–74.
58. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology. 2012;217:1122–1128.
59. Ma YJ, Doni A, Skjoedt MO, et al. Heterocomplexes of mannose-binding lectin and the pentraxins PTX3 or serum amyloid P component trigger cross-activation of the complement system. J Biol Chem. 2011;286:3405–3417.
60. Lu J, Marjon KD, Mold C, Du Clos TW, Sun PD. Pentraxins and Fc receptors. Immunol Rev. 2012;250:230–238.
61. Maury CP, Helve T, Sjoblom C. Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int. 1982;2:145–149.
62. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4(Suppl 3):S279–293.
63. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature. 1979;278:259–261.
64. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5:694–697.
65. Lech M, Rommele C, Kulkarni OP, et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS ONE. 2011;6:e20118.
66. Gaboriaud C, Ling WL, Thielens NM, Bally I, Rossi V. Deciphering the fine details of c1 assembly and activation mechanisms: “mission impossible”? Frontiers Immunol. 2014;5:565.
67. Sjoberg AP, Trouw LA, McGrath FD, Hack CE, Blom AM. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol. 2006;176:7612–7620.
68. Braunschweig A, Jozsi M. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PLoS ONE. 2011;6:e23991.
69. Schwalbe RA, Dahlback B, Nelsestuen GL. Independent association of serum amyloid P component, protein S, and complement C4b with complement C4b-binding protein and subsequent association of the complex with membranes. J Biol Chem. 1990;265:21749–21757.
70. Bykov I, Junnikkala S, Pekna M, Lindros KO, Meri S. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin Immunol. 2007;124:213–220.
71. Pangburn MK, Muller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol. 1984;7:163–192.
72. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15:369–396.
73. Meri S. Self-nonself discrimination by the complement system. FEBS Lett. 2016;590:2419–2434.
74. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A. 1990;87:3982–3986.
75. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol. 2010;25:2431–2442.
76. Hyvarinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood. 2016;127:2701–2710.
77. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24:496–502.
78. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol. 1999;163:3957–3962.
79. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. 2007;178:3831–3836.
80. Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem. 2010;285:1053–1065.
81. Hellwage J, Jokiranta TS, Friese MA, et al. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol. 2002;169:6935–6944.
82. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem. 2000;275:27657–27662.
83. Kajander T, Lehtinen MJ, Hyvarinen S, et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A. 2011;108:2897–2902.
84. Morgan HP, Schmidt CQ, Guariento M, et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol. 2011;18:463–470.
85. Sjoberg AP, Trouw LA, Clark SJ, et al. The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem. 2007;282:10894–10900.
86. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227–7232.
87. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389.
88. Seitsonen S, Lemmela S, Holopainen J, et al. Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Mol Vis. 2006;12:796–801.
89. Clark SJ, Ridge LA, Herbert AP, et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol. 2013;190:2049–2057.
90. Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood: III. Immunological properties of the C-reactive protein and its differentiation from normal blood proteins. J Exp Med. 1941;73:191–200.
91. Meri T, Amdahl H, Lehtinen MJ, et al. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog. 2013;9:e1003308.
92. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Bjorck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol. 2002;168:1886–1894.
93. Mold C, Kingzette M, Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol. 1984;133:882–885.
94. Huttunen R, Hurme M, Aittoniemi J, et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS ONE. 2011;6:e17653.
95. Daigo K, Yamaguchi N, Kawamura T, et al. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol Cell Proteomics. 2012;11(M111):015073.
96. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–1535.
97. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol. 2012;189:2689–2695.
98. Urban CF, Ermert D, Schmid M, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009;5:e1000639.
99. Savchenko AS, Inoue A, Ohashi R, et al. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011;61:290–297.
100. Razvina O, Jiang S, Matsubara K, et al. Differential expression of pentraxin 3 in neutrophils. Exp Mol Pathol. 2015;98:33–40.
101. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P. Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis. 2009;49:1044–1050.
102. Soehnlein O, Lindbom L. Neutrophil-derived azurocidin alarms the immune system. J Leukoc Biol. 2009;85:344–351.
103. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93:185–198.
104. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318–1321.
105. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011;118:3708–3714.
106. Jeannin P, Bottazzi B, Sironi M, et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity. 2005;22:551–560.
107. Bozza S, Bistoni F, Gaziano R, et al. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood. 2006;108:3387–3396.
108. Job ER, Bottazzi B, Short KR, et al. A single amino acid substitution in the hemagglutinin of H3N2 subtype influenza A viruses is associated with resistance to the long pentraxin PTX3 and enhanced virulence in mice. J Immunol. 2014;192:271–281.
109. Job ER, Deng YM, Tate MD, et al. Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J Immunol. 2010;185:4284–4291.
110. Foo SS, Reading PC, Jaillon S, Mantovani A, Mahalingam S. Pentraxins and collectins: friend or foe during pathogen invasion? Trends Microbiol. 2015;23:799–811.
111. Gunn BM, Morrison TE, Whitmore AC, et al. Mannose binding lectin is required for alphavirus-induced arthritis/myositis. PLoS Pathog. 2012;8:e1002586.
112. Cotena A, Maina V, Sironi M, et al. Complement dependent amplification of the innate response to a cognate microbial ligand by the long pentraxin PTX3. J Immunol. 2007;179:6311–6317.
113. Lech M, Rommele C, Grobmayr R, et al. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. 2013;83:647–661.
114. Schneider LA, Korber A, Grabbe S, Dissemond J. Influence of pH on wound-healing: a new perspective for wound-therapy? Arch Dermatol Res. 2007;298:413–420.
115. Xiao Y, Yang N, Zhang Q, Wang Y, Yang S, Liu Z. Pentraxin 3 inhibits acute renal injury-induced interstitial fibrosis through suppression of IL-6/Stat3 pathway. Inflammation. 2014;37:1895–1901.
116. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055–1064.
117. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699–708.
118. Paeschke A, Possehl A, Klingel K, et al. The immunoproteasome controls the availability of the cardioprotective pattern recognition molecule Pentraxin3. Eur J Immunol. 2016;46:619–633.
119. Rovere-Querini P, Antonacci S, Dell'AntonioG, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–155.
120. Ravizza T, Moneta D, Bottazzi B, et al. Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience. 2001;105:43–53.
121. Rodriguez-Grande B, Swana M, Nguyen L, et al. The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury. J Cereb Blood Flow Metab. 2014;34:480–488.
122. Real JM, Spilborghs GM, Morato-Marques M, et al. Pentraxin 3 accelerates lung injury in high tidal volume ventilation in mice. Mol Immunol. 2012;51:82–90.
123. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–1081.
124. Choi B, Lee EJ, Song DH, et al. Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget. 2014;5:481–492.
125. Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res. 2011;17:2395–2399.
126. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235–2244.
127. Infante M, Allavena P, Garlanda C, et al. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. Int J Cancer. 2016;138:983–991.
128. Stallone G, Cormio L, Netti GS, et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014;74:4230–4238.
129. Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23:116–122.
130. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198–5208.
131. Wang JX, He YL, Zhu ST, Yang S, Zhang ST. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:4225–4230.
132. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286–291.
133. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
134. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444.
135. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35:229–244.
136. Chang WC, Wu SL, Huang WC, et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget. 2015;6:7741–7757.
137. Choi B, Lee EJ, Park YS, et al. Pentraxin-3 silencing suppresses gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res. 2015;35:2663–2668.
138. Kondo S, Ueno H, Hosoi H, et al. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer. 2013;109:739–746.
139. Tung J-N, Ko C-P, Yang S-F, et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. J Neurooncol. 2016;129:201–209.
140. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–641.
141. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349–2354.
142. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.
143. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57:861–869.
144. Latini R, Gullestad L, Masson S, et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012;14:992–999.
145. Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc. 2014;3:e000928.
146. Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:976–985.
147. Suliman ME, Qureshi AR, Carrero JJ, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM. 2008;101:397–405.
148. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in chronic kidney disease patients: association with renal function, protein-energy wasting, cardiovascular disease and mortality. Clin J Am Soc Nephrol. 2007;2:889–897.
149. Sjoberg B, Qureshi AR, Heimburger O, et al. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. J Intern Med. 2016;279:173–179.
150. Sjoberg B, Qureshi AR, Anderstam B, Alvestrand A, Barany P. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation. Blood Purif. 2012;34:290–297.
151. Sjoberg B, Snaedal S, Stenvinkel P, Qureshi AR, Heimburger O, Barany P. Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. Clin Kidney J. 2014;7:373–379.
152. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29:594–599.
153. Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM. Associations of pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosis. J Thromb Haemost. 2014;12:999–1005.
154. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012;163:274–279.
155. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404–1407.
156. Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS ONE. 2013;8:e73119.
157. Uusitalo-Seppala R, Huttunen R, Aittoniemi J, et al. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS ONE. 2013;8:e53661.
158. Mauri T, Bellani G, Patroniti N, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010;36:621–629.
159. Ristagno G, Varpula T, Masson S, et al. Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death. Clin Chem Lab Med. 2015;53:1847–1857.
160. Azzurri A, Sow OY, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005;7:1–8.
161. Mairuhu AT, Peri G, Setiati TE, et al. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol. 2005;76:547–552.
162. Sprong T, Peri G, Neeleman C, et al. Ptx3 and C-reactive protein in severe meningococcal disease. Shock. 2009;31:28–32.
163. Wagenaar JF, Goris MG, Gasem MH, et al. Long pentraxin PTX3 is associated with mortality and disease severity in severe leptospirosis. J Infect. 2009;58:425–432.
164. Biagi E, Col M, Migliavacca M, et al. PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. J Pediatr Hematol Oncol. 2008;30:881–885.
165. Mauri T, Coppadoro A, Bombino M, et al. Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study. Crit Care. 2014;18:562.
166. Hansen MB, Rasmussen LS, Garred P, Bidstrup D, Madsen MB, Hyldegaard O. Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study. Crit Care. 2016;20:1–11.
167. Olesen R, Wejse C, Velez DR, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tubercolosis risk in West Africans. Genes Immun. 2007;8:456–467.
168. Chiarini M, Sabelli C, Melotti P, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun. 2010;11:665–670.
169. Wojtowicz A, Lecompte TD, Bibert S, et al. PTX3 polymorphisms and invasive mold infections after solid organ transplant. Clin Infect Dis. 2015;61:619–622.
170. Barbati E, Specchia C, Villella M, et al. Influence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels. PLoS ONE. 2012;7:e53030.
171. Ma YJ, Doni A, Hummelshoj T, et al. Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition. J Biol Chem. 2009;284:28263–28275.
172. Gout E, Moriscot C, Doni A, et al. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J Immunol. 2011;186:5815–5822.
173. van den Blink B, Dillingh MR, Ginns LC, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J. 2016;47:889–897.
174. Dillingh MR, van den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. 2013;26:672–676.